EPA guidance on the early intervention in clinical high risk states of psychoses by Schmidt, S. J. et al.
1 
 
EPA guidance on the early intervention in clinical high-risk states of psychoses 
Stefanie J. Schmidt1, Frauke Schultze-Lutter1, Benno G. Schimmelmann1, Nadja P. Maric3, 
Raimo R.K. Salokangas4, Anita Riecher-Rössler5, Mark van der Gaag6, Anna Meneghelli7, 
Merete Nordentoft8, Max Marshall9, Anthony Morrison10, Joachim Klosterkötter2, Stephan 
Ruhrmann2 
 
 
1
 University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, 
Bern, Switzerland 
2
 Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany 
3
 School of Medicine, University of Belgrade and Clinic of Psychiatry, Clinical Center of Serbia, 
Belgrade, Serbia 4 Turku, Finland 
5
 Basel, Switzerland 
6
 Amsterdam, The Netherlands 
7
 Milano, Italy 
8
 Copenhagen, Denmark 
9
 Manchester, UK 
10
 Manchester, UK 
 
  
2 
 
Abstract 
The aim of this guidance paper of the European Psychiatric Association (EPA) is to provide 
evidence-based recommendations on the early intervention in clinical high-risk (CHR) states of 
psychoses as assessed according to the EPA guidance on early detection. These 
recommendations were derived from the current empirical evidence and a meta-analysis on the 
efficacy of psychological and pharmacological interventions in CHR samples. Studies had to 
investigate conversion rate and/or functioning as treatment outcome in CHR patients defined by 
the ultra-high risk and/or basic symptom criteria. Besides analyses on treatment effects on 
conversion rate and functional outcome, age and intervention approach were examined as 
potential moderators. Based on data of 15 studies (n=1394), early intervention approaches 
generally produced significantly reduced conversion rates at 6- to 48-month follow-ups 
compared to the control conditions. However, they failed to achieve significantly greater 
functional improvements because both early intervention and control conditions produced similar 
positive effects. With regard to the intervention approach, both psychological and 
pharmacological interventions produced significant effects on conversion rates but not on 
functional outcome relative to the control conditions. Early intervention in youth samples was 
generally less effective than in predominantly adult samples. Six evidence-based 
recommendations for an early intervention in CHR samples could already be formulated 
although more studies to investigate the specificity of treatment effects and potential age effects 
in order to tailor interventions to the individual treatment needs and risk status are clearly 
needed. 
 
Key words: prevention, early intervention in Europe, meta-analysis, risk, psychosis, 
adolescents, youth, cognitive-behavioral therapy, antipsychotics, neuro-protective  
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1. Introduction  
Each year 38.2% of the population of the European Union, i.e., 164.8 million persons, suffer 
from any mental disorder (Wittchen et al., 2011). This is associated with huge societal and 
individual burden (Gustavsson et al., 2011; Whiteford et al., 2013). Prevention has therefore 
become an integral part of European and international health care policies in order to reduce the 
prevalence and burden of mental disorders across the lifespan (EC, 2005, 2008; Campion et al., 
2012; Haro et al., 2014).  
 
1.1. Functional disability in psychotic disorders 
Schizophrenia is among the seven leading causes of years lost to disability (YLDs) in adults in 
Europe (Wittchen et al., 2011). This is mainly due to the fact that functional recovery rates have 
not changed substantially over the past 25 years, despite advances in pharmacological and 
psychological treatments (Jääskeläinen et al., 2013, Shivashankar et al., 2013). As a 
consequence, prevention of schizophrenia and psychotic disorders in general has attracted 
special interest (Solis, 2014).  
Functional impairments are already present before (Addington et al., 2011) and often worsen 
until the onset of psychosis (Häfner et al., 1999). Furthermore, they are one of the main 
predictors of poor clinical outcome including conversion to psychosis (Granö et al., 2014). This 
emphasizes the need to intervene as early as possible to avoid or at least diminish these 
burdens and thereby to prevent transition to manifest psychosis.  
 
1.2. Prevention in clinical high risk states of psychoses 
In psychosis research, an indicated prevention approach has been adopted that targets help-
seeking persons who experience early signs of the emerging psychosis but do not meet 
diagnostic criteria with the ultimate goal to prevent the incidence of the disorder (McGlashan & 
Johannesson, 1999; McGorry et al., 1998, 2002). Thus, indicated prevention faces two 
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challenges: (1) the accurate identification of the target population and (2) their effective 
treatment. For the purpose of early detection, two complementary sets of clinical high risk (CHR) 
criteria have been developed: the basic symptom (Huber, 1966; Schultze-Lutter, 2009) and the 
ultra-high risk (UHR) approach (Miller et al., 2003; Yung et al., 2005). Their evidence is 
systematically reviewed by and recommendations for their use are given in the accompanying 
European guidance on early detection (see Schultze-Lutter et al., this issue). Notably, fulfilling 
these criteria only indicates an increased risk for developing psychosis which is always 
associated with an error probability resulting in false-positive predictions (Ruhrmann et al., 
2010). This has fueled ongoing debates about the risk of negative effects associated with the 
identification and treatment of CHR states of psychoses (e.g., stigmatization, financial loss) (e.g., 
Fusar-Poli et al., 2014; Nelson, 2014; ethics-chapter).  
 
1.3. Need for treatment in clinical high risk states of psychoses 
In addition to the markedly increased risk for developing psychosis (Schultze-Lutter et al., this 
issue), the most important argument in favor of an intervention in CHR patients is the reported 
distress and stigmatization caused by their mental problems already at the time of referral to an 
early detection and intervention service (Kline et al., 2014; Rüsch et al., 2014a,b; Stowkowy et 
al., 2014). This is reflected by their even higher levels of hopelessness, depressiveness, anxiety, 
and poor quality of life in comparison to other help-seeking patients and patients with first-
episode psychosis (Bechdolf et al., 2005; Lee et al., 2011; Pruessner et al., 2011; Granö et al., 
2014a,b). Accordingly, they often fulfill the diagnostic criteria for another mental disorder, in 
particular for depression, anxiety, and substance abuse or dependence, which require treatment 
(Woods et al., 2009; Hui et al., 2013; Fusar-Poli et al., 2014). Furthermore, CHR patients exhibit 
poor coping skills, low self-efficacy, and excessive external attributions that resemble profiles of 
depressive patients and might unfavorably interact with their frequent depressive mood (Schmidt 
et al., 2014).  
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In addition, CHR patients demonstrate abnormalities in neuro- and social cognition with 
performances that are usually intermediate between those of healthy controls and schizophrenia 
patients (Fusar-Poli et al., 2013; Giuliano et al., 2013; Thompson et al., 2013; Bora et al., 2014; 
Brent et al., 2014), and are associated with markedly impaired functional outcome and negative 
symptoms (Addington et al., 2009; Lin et al., 2011; Carrion et al., 2013; Olvet et al., 2013; Granö 
et al., 2014; Salokangas et al., 2014). Consistent with the conceptualization of psychoses as 
neurodevelopmental disorders, these neuro- and social-cognitive abnormalities are also 
accompanied and possibly reflected by various abnormalities in functional and structural imaging 
(Smieskova et al., 2013; Bois et al., 2014), in electrophysiological measures (Higuchi et al., 
2013; Kayser et al., 2014) and neurochemistry (Leweke et al., 2012; Egerton et al., 2014; Gran 
et al., 2014). In summary, CHR patients are – independent of any potential risk to develop 
psychosis in the future – certainly in need for treatment (Ruhrmann et al. 2010). 
 
1.4. Requirements for early intervention approaches  
In accordance with this obvious need for treatment, an increasing number of interventions have 
been evaluated in CHR samples in recent years (Ruhrmann et al., 2012; Okuzawa et al., 2014; 
Stafford et al., 2014). With the primary goal to prevent conversion to psychosis, they have mainly 
built upon well-established interventions for adult schizophrenia patients and used conversion to 
psychosis as their primary outcome (McGorry et al., 2002; Morrison et al., 2004). Other more 
recently developed interventions have taken into account that CHR patients not only suffer from 
risk symptoms but also from several other mental problems and have targeted a broader array of 
outcomes in various settings with various intervention techniques (e.g., intensive case 
management, multi-family psychoeducation) (Granö et al., 2014a,b; Marvin et al., 2014). Yet 
most “new generation” intervention studies have an uncontrolled single-group design, therefore 
lack methodological rigor, and were not included in recent meta-analyses on the efficacy of 
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randomized controlled trials (RCTs) in CHR states (Cella & Preti, 2010; Marshall & Rathbone, 
2011; Fusar-Poli et al., 2013; van der Gaag, 2013; Stafford et al., 2013; Hutton & Taylor, 2014).  
Current guidelines have not considered these “new generation” interventions (DGPPN, IEPA; 
NICE). Moreover, no sufficient evidence-based differential indication for the available 
interventions exists, which would require the examination of the treatment approach as a 
potential moderator variable in meta-analyses and/or in direct comparison in large RCTs with 
multiple treatment arms. In this context, age should also be studied as a potential moderator 
because CHR samples commonly include adolescents and young adults who differ in their 
social, emotional, and cognitive developmental state. 
 
1.4. Aims 
The main aim of this guidance paper on the early intervention in CHR states was therefore to 
evaluate the efficacy of intervention approaches in CHR patients that focus on both prevention of 
conversion to psychosis and improvement in functional outcome with special consideration of 
the potential moderating effects of age and intervention type. This served the ultimate goal to 
derive evidence-based recommendations on early intervention in CHR states assessed 
according to the recommendations provided by the EPA guidance on their early detection (see 
[Schultze-Lutter et al.], this issue). 
 
2. Methods 
2.1. Study selection 
2.1.1. Literature search  
We conducted a systematic literature search in June 2014 in PubMed (no time limit), PsycInfo 
(no time limit), Scopus (no time limit) that covers all journals included in Embase, and in the 
Cochrane Collaboration Controlled Trials Register using the following search terms and syntax: 
((prevention) OR (early intervention) OR (treatment) OR (therapy)) AND ((risk) OR (prodrome) 
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Study Coun
-try 
De-
sign 
In- & exclusion 
criteria 
Sample 
size 
Sample 
characteristics 
Inter-
vention 
Control 
group 
Follow-up 
(months after 
baseline); 
Dropout-rate 
(Post-
therapy) 
Extracted 
outcome 
 
Morrison 
et al., 
2004 [x], 
2007 [x]; 
 
GE 1
- 
 
 
 
UK RCT Inclusion criteria: 
- Risk for psychosis (PANSS) 
Exclusion criteria: 
- < 16 years, > 36 years 
- Current or past receipt of 
antipsychotic medication 
60 
EG: 37 
CG: 23 
- Age (yrs.):  
EG: 20.6±4.9 / CG: 
21.5±5.2 (Age 
group: ADULT) 
- Gender: 
(male): EG: 60% / 
CG: 83% 
- Co-morbidities: not 
reported 
CBT + 
monitoring; 
26 sessions, 
6 months 
Monitoring; 
monthly  
6, 12, 36; 
EG / CG: 30% 
/ 30% 
TR (PANSS) 
Addington 
et al., 
2011 [x]; 
Marshall 
et al., 
2012 [x]; 
 
GE 1
- 
 
 
CAN RCT Inclusion criteria 
- 14 to 30 years 
- Risk for psychosis (SIPS) 
Exclusion criteria 
- Lifetime or  
current axis-I psychotic 
disorder 
- Prior treatment with an 
antipsychotic 
- IQ < 70 
- Past/current central nervous 
system disorder 
51  
EG: 27 
CG: 24  
- Age (yrs.): EG: 
20.8±4.5 / CG: 
21.1±3.7 (Age 
group: ADULT) 
- Gender (male): EG: 
67% / CG 75% 
- Co-morbidities (EG 
/ CG): mood 
disorders: 26% / 
26%, alcohol abuse: 
18% / 18%, 
cannabis abuse: 
10% / 10% 
CBT; 
max. 20 
sessions 
(mean=12±6
.2, range=1-
26),  
6 months 
Supportive 
Therapy: 
coping with 
current 
problems, 
psycho-
education; 
20 sessions, 
6 months 
6, 12, 18;  
EG / CG: 30% 
/ 33%,  
TR (SIPS), FO 
(GAF & SFS)  
Morrison 
et al., 
2012, 
UK RCT Inclusion criteria: 
- At-risk for psychosis 
(CAARMS) 
288 
EG: 144 
CG: 
- Age (yrs.): EG: 
20.7±4.2 / CG: 
20.8±4.5 (Age 
CBT + 
Monitoring; 
Max. 26 
Monitoring; 
monthly 
 
6, 12, 18, 24; 
EG / CG: 33% 
/ 31% 
TR (CAARMS 
or reports 
from family 
Tab. 1 Characteristics of studies included in the meta-analysis 
 [x]; 
Morrison 
et al., 
2011, 
2013 [x]; 
 
GE 1
+
 
- 14-35 years 
- Help-seeking 
Exclusion criteria: 
- Current or previous receipt of 
antipsychotic drugs 
- Moderate to severe learning 
disability 
- Organic impairments 
- Insufficient English 
144 group: ADULT) 
- Gender: (male): EG: 
62% / CG: 63% 
- Co-morbidities 
(total sample, >5%): 
Depressive 
disorder: 34%, 
dysthymic disorder: 
7%, panic disorder 
with agoraphobia: 
6%, panic disorder 
without 
agoraphobia: 11%, 
social phobia: 11%, 
specific phobia: 
11%, generalized 
anxiety disorder: 
9%, obsessive 
compulsive 
disorder: 8% 
sessions, 6 
months; 
plus up to 4 
booster-
sessions in 
the 
following 6 
months; 
 
 doctors), FO 
(GAF) 
Bechdolf 
et al.,  
2012 [x]; 
Bechdolf 
et al., 
2007 [x]; 
 
GE 1
-
 
GER RCT Inclusion criteria: 
- At least one of 10 thought or 
perceptional basic symptoms 
(ERIraos) and/or  
- Reduction in the GAF Score 
(DSM-IV) of at least 30 points 
within the past year and at 
least one of these risk factors: 
first-degree relative with 
schizophrenia  /schizophrenia 
spectrum disorder or pre-
/perinatal complications;  
Exclusion criteria: 
- APS or BLIPS 
- Present or past diagnosis of a 
psychotic disorder, bipolar 
disorder, organic brain 
128  
EG: 63 
CG: 65 
- Age (yrs.): EG: 
25.2±5.4 / CG: 
26.8±6.2 (Age 
group: ADULT) 
- Gender: (male): 
62% / 65%  
- Co-morbidities: not 
reported 
 
Integrated 
treatment: : 
Individual 
CBT, multi- 
family 
psycho-
education 
(group), 
social skills 
training 
(group), 
cognitive 
remediation 
25 sessions, 
12 months 
Supportive 
counselling: 
coping with 
current 
problems, 
basic 
psycho-
education; 
30 sessions, 
12 months 
 
6, 12, 18, 24; 
EG / CG: 19%, 
/ 
12%  
TR (DSM-IV), 
FO (SAS II) 
disorder, substance 
dependence 
- Mental retardation 
- Previous treatment with 
antipsychotics 
- Acute suicidality 
- < 17 years, > 35 years 
Van der 
Gaag et 
al., 2012 
[x]; 
Rietdijk et 
al., 2010 
[x]; 
 
GE 1
++
 
 
NL RCT Inclusion criteria 
- 14 to 35 years 
- At-risk for psychosis (CAARMS 
2006)  
- SOFAS score ≤ 50 and/or a 
reduction by 30% for at least 
1 month in the past year 
Exclusion criteria: 
- Current or previous use of 
antipsychotic medication with  
≥ 15 mg cumulative 
haloperidol equivalent 
- Severe learning impairment 
- Problems due to an organic 
condition 
- Insufficient competence in 
Dutch;  
- History of psychosis 
201  
EG: 98 
CG: 
103 
- Age (yrs.): EG: 
22.9±5.6 / CG: 
22.6±5.5 (Age 
group: ADULT) 
- Gender (male): EG: 
50% / CG:   
49% 
- Co-morbidities: 
(total sample, > 
5%): Anxiety 
disorders: 27%, 
depression: 26%, 
personality 
disorders: 8%, 
ADHD: 7%, 
addiction problems: 
6%;  
CBT + 
Treatment 
As Usual 
(TAU);  
max. 26 
sessions, 
weekly; 
6 months; 
additional 
evidence-
based 
treatment 
for axis-I 
and axis-II 
disorders; 
Treatment 
As Usual 
(TAU);  
additional 
evidence-
based 
treatment 
for axis-I 
and axis-II 
disorders; 
6, 12, 18; 
EG / CG: 15% 
/ 12% 
TR (CAARMS 
2006), FO 
(SOFAS) 
McGorry 
et al., 
2013 [x]; 
Yung et al. 
2011 [x]; 
 
GE 1
+ 
 
AUS RCT Inclusion criteria: 
- Age 14-30 years 
- Melbourne metropolitan area 
- Risk for psychosis (CAARMS 
2006) 
Exclusion criteria: 
- History of psychotic or manic 
episode 
- Medical condition that 
accounts for symptoms 
- Neurologic, biochemical or 
72 
EG: 44 
CG: 28 
- Age (yrs.): EG: 
18.0±2.7 / CG: 
18.8±3.7 (Age 
group: YOUTH) 
- Gender (male): EG: 
49% / CG: 47%  
- Co-morbidities: not 
reported 
EG : CBT + 
Placebo; 12 
months; 
CBT: Weekly 
to monthly 
basis; 50-60 
min./session
with the 
number of 
sessions not 
determined 
Supportive 
therapy + 
placebo; 12 
months; 
6, 12; 
EG: 34% / CG: 
32% 
TR (CAARMS 
2006), FO 
GAF) 
hematologic abnormalities 
- Serious co-existing illnesses 
- Lifetime antipsychotic dose of 
15mg or more of haloperidol  
- Any previous or current use 
of mood-stabilizing 
medication 
- History of severe drug allergy 
-  IQ<70 
- Pregnancy or lactation 
- Insufficient English  
in advance; 
Miklowitz 
et al., 
2014 [x]; 
O’Brien et 
al., 2014 
[x]; 
 
GE 1
+ 
USA RCT Inclusion criteria: 
- 12 and 25 years  
- Speaks and writes English 
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- Current schizophrenia or 
schizoaffective disorders 
- Developmental disorders 
- Substance use disorders 
- Neurological disorders 
129 
EG: 66 
CG: 63 
- Age (yrs.): EG: 
17.3±4.2 / CG: 
17.4±3.9 (Age 
group: YOUTH) 
- Gender (male): EG: 
59 % / CG: 56%  
- Co-morbidities (EG 
/ CG, >10%): 
depressive disorder 
(40% / 29%), 
anxiety disorders 
(42% / 50%), ADD 
(21% / 18%), 
learning disorders 
(11% / 7%) 
Family 
focused 
treatment; 
18 sessions 
à 60 
minutes, 6 
months 
 
Enhanced 
care; 
3 weekly 
psycho-
educational 
sessions, 
1 month 
6; 
EG: 17% / CG: 
25% 
 
TR (SIPS), FO 
(GAF) 
O’Brien et 
al., 2007 
[x]; 
 
GE 2
-
 
USA No 
CG 
Inclusion criteria: 
- 12-22 years  
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- DSM-IV diagnosis of a 
schizophrenia spectrum 
disorder 
- IQ<70 
- Current drug or alcohol 
dependence 
16   - Age (yrs.): 15.7 
(range: 12.5-18.5) 
(Age group: 
YOUTH) 
- Gender: (male): 
50%  
- Comorbidities  
(>10%): Mood 
disorders: 63%, 
depressive 
Psycho-
educational 
multi-family 
group; 
Weekly 
sessions à 
90 minutes, 
9 months 
- 9; 
45% declined 
or dropped 
out 
FO (GAF) 
- Current neurological disorder disorder: 31%, 
depressive disorder 
NOS: 19%, anxiety 
disorder NOS: 31%, 
generalized anxiety 
disorder: 19%, 
ADHD: 13%, eating 
disorder NOS: 19% 
/ 0% 
Hooker et 
al., 2014 
[x]; 
 
GE 2
-
 
USA  No 
CG 
Inclusion criteria: 
- 15-35 years 
- At-risk for psychosis (SIPS)  
Exclusion criteria: 
- Major medical / neurological 
illness 
- Non-fluent English 
- MR-contraindication 
- IQ<70 
28 
EG: 14 
CG: 14 
- Age (yrs.): 21.9±4.2 
(Age group: ADULT) 
- Gender (male): 50% 
CRT; neuro- 
and social-
cognitive 
computerize
d exercises; 
1h each day, 
5 
days/week, 
8 weeks; 
- 3; 
18%  
FO (Global 
Functioning 
Role and 
Social scales) 
Pharmacological studies - with antipsychotics – (MED)  
McGlasha
n et al., 
2006 [x]; 
McGlasha
n et al., 
2003 [x]; 
Woods et 
al., 2003 
[x]; 
 
GE 1
+
 
USA  RCT Inclusion criteria: 
- 12-45 years 
- Help-seeking 
- At-risk for psychosis (SIPS)¨ 
Exclusion criteria: 
- Past or current psychotic 
disorder 
- Treatable psychiatric disorder 
that could account for the 
prodromal symptoms 
- Suicidal or homicidal 
- Prodromal symptoms due to 
drug/alcohol use 
60 
EG:31 
CG: 29 
- Age (yrs.): EG: 
18.2±5.5 / CG: 
17.2±4.0 (Age 
group: YOUTH) 
- Gender (male): EG: 
68% / CG: 62% 
- Co-morbidities: 
Current substance 
abuse or 
dependence (EG: 
13% / CG: 4%)  
Olanzapine; 
5-15 mg/d, 
12 months; 
Additional 
individual  
and family 
psychosocial 
treatment, 
varied 
across sites; 
 
Placebo; 
12 months; 
Additional 
individual  
and family 
psychosocia
l treatment, 
varied 
across sites; 
 
2, 12, 24; 
EG: 55% / CG: 
35% 
 
TR (SIPS), FO 
(GAF) 
Woods et 
al., 2007 
[x]; 
 
USA No 
CG 
Inclusion criteria: 
- 13-40 years 
- Treatment seeking 
outpatients 
15 - Age (yrs.): 17.1±5.5 
(Age group: 
YOUTH) 
- Gender (male): 53% 
Aripiprazole
;  
Initial doses 
were 1st 
- 2; 
13% 
FO (GAF, SFS) 
GE 2
-
 - Met diagnostic criteria for a 
possible prodromal syndrome 
(SIPS) 
Exclusion criteria: 
- Past or current DSM-IV 
criteria for any lifetime 
psychotic disorder 
- Psychiatric disorder which 
could account for the 
symptoms 
- Symptoms primarily as 
sequelae to drug or alcohol 
use 
- Alcohol or drug misuse or 
dependence in the past 3 
months 
- Use of antipsychotic 
medication in the previous 3 
months 
- Change in dosage of any 
antidepressant within 6 
weeks, stimulant medication 
within 4 weeks or mood 
stabiliser within 4 weeks 
- Co-morbidities: not 
reported 
Week: 5 
mg/d, 2nd 
Week: 10 
mg/d 
3rd week: 
15 mg/d, 
4th Week: 
20mg/d and 
if needed to 
30mg/d; 
6 weeks  
Tsujino et 
al., 2013 
[x]; 
 
GE 2
-
 
JPN No 
CG 
Inclusion criteria: 
- 15-39 years 
- Help-seeking outpatients 
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- Previous diagnosis of any 
psychotic disorder (DSM-IV) 
- Symptoms fully accounted for 
by an Axis 1 disorder or 
sequelae of drug/alcohol use 
- Abuse of alcohol or drugs 
- Antipsychotic medication use 
11 - Age (yrs.): 26.7±6.5 
(Age group: ADULT)  
- Gender (male): 46% 
- Co-morbidities: not 
reported 
Perospirone
; dosing 
according to 
a flexible 
schedule; 
psychosocial 
therapy 
available;  
26 weeks 
- 6; 
25% 
 
FO (GAF) 
Pharmacological studies - combined with psychological interventions – (MED)  
McGorry 
et al. 2002 
[x]; Phillips 
et al., 
2007 [x]; 
 
GE 1
- 
 
AUS RCT Inclusion criteria: 
- 14-30 years 
- Live in the Melbourne 
metropolitan area 
- Risk for psychosis (CAARMS) 
Exclusion criteria: 
- Previous psychotic or manic 
episode 
- Previous treatment with an 
antipsychotic or mood 
stabilizing agent 
- Substance-induced psychotic 
disorder 
- IQ<70 
- Inadequate command of 
English 
59 
EG: 31 
CG: 28 
- Age (yrs.): EG: 
20±4/ CG: 20±3 
(Age group: ADULT) 
- Gender (male): EG: 
65% / CG: 50% 
Risperidone 
(1-2 mg/d) +  
CBT + 
Needs-
based 
intervention
(NBI); 
6 months; 
NBI on-
going;  
Needs-
based 
interventio
n (NBI);  
6 months; 
NBI on-
going; 
 
6, 12, 36-48; 
months; 
Drop-out 
rate: not 
reported, 
41% non-
adherent to 
Risperidone;  
 
FO (GAF) 
Ruhrmann 
et al., 
2007 [x]; 
 
GE 1
-
 
GER RCT Inclusion criteria: 
- Older than 18 years  
- Risk for psychosis (ERIraos) 
Exclusion criteria: 
- Lifetime DSM–IV diagnosis of 
schizophrenia spectrum 
disorder, brief psychotic 
episode (>1 week), delirium, 
dementia, amnestic and 
other cognitive disorders 
- Mental retardation 
- Mental disorders due to a 
general medical condition or 
psychotropic substances 
- Abuse of alcohol or drugs 
within the past 3 months or 
the past 4 weeks for cannabis 
- Any lifetime continuous 
treatment with high-potency 
124 
EG: 65 
CG: 59 
- Age (yrs.): EG: 
25.1±6.6 / CG: 
26.1±6.1 (Age 
group: ADULT) 
- Gender: (male): 
48% / 60% 
- Co-morbidities: not 
reported 
Needs-
focused 
intervention 
+ 
Amisulpride; 
12 weeks; 
50-800 
mg/d, with 
increments 
of 50 mg at 
first step 
and 100 mg 
at further 
steps; 
dosage was 
increased as 
long as APS 
and BLIPS 
were 
Needs-
focused 
interventio
n; 
12 weeks 
3; 
EG: 29% / CG: 
49%  
FO (GAF) 
antipsychotics (> 1 week) or 
antipsychotics during 6 
months prior to the study 
- Any contraindication for 
amisulpride  
- Women of childbearing risk 
not using contraception 
present;  
McGorry 
et al., 
2013 [x]; 
Yung et al. 
2011 [x]; 
 
GE 1
+ 
 
AUS RCT Inclusion criteria: 
- Age 14-30 years 
- Melbourne metropolitan area 
- Risk for psychosis (CAARMS, 
2005) 
Exclusion criteria: 
- History of psychotic or manic 
episode 
- Medical condition that 
accounts for symptoms 
- Neurologic, biochemical or 
hematologic abnormalities 
- Serious co-existing illnesses 
- Lifetime antipsychotic dose of 
15mg or more of haloperidol  
- Any previous or current use 
of mood-stabilizing 
medication 
- History of severe drug allergy 
- IQ<70 
- Pregnancy or lactation 
- Insufficient English  
71 
EG: 43
 
CG: 28 
- Age (yrs.): EG: 17.6 
±3.0) / CG: 18.8±3.7 
Age group: YOUTH) 
- Gender (male): EG: 
45% / CG: 47%  
- Co-morbidities: not 
reported 
EG: CBT + 
Risperidone 
(0.5-2 
mg/d);  
12 months; 
CBT: Weekly 
to monthly 
basis; 50-60 
min./session
; number of 
sessions not 
predetermin
ed; 
 
Supportive 
therapy + 
placebo;  
12 months; 
6, 12; 
EG 37% / CG: 
32% 
TR (CAARMS 
2006), FO 
GAF) 
Pharmacological studies - with nutritional supplements – (MED)  
Amminger 
et al., 
2010 [x]; 
Mossaheb 
et al., 
2013 [x]; 
AUT RCT Inclusion criteria: 
- At-risk for psychosis (PANSS) 
Exclusion Criteria: 
- History of previous psychotic 
disorder or manic episode  
- Substance-induced psychotic 
81 
EG: 41 
CG:40  
- Age (yrs.): EG: 
16.8±2.4 / CG: 
16.0±1.7 (Age 
group: YOUTH) 
- Gender (male): EG: 
34% / CG: 33% 
1.2 g/d ω-3 
PUFAS; 
12 weeks;  
9 additional 
sessions of 
psychologic
Placebo 
(coconut 
oil); 
12 weeks; 
psychologic
al and 
12;  
EG: 7% / 5%;  
TR (PANSS), 
FO (GAF) 
 GE 1
+
 
 
 
disorder 
- Acute suicidal or aggressive 
behavior 
- Current DSM-IV diagnosis of 
substance dependence 
(except cannabis 
dependence) 
- Neurological disorders  
- IQ<70 
- Structural brain changes 
apparent on magnetic 
resonance imaging 
- Previous treatment with an 
antipsychotic or mood-
stabilizing agent (>1 week) 
- ω-3 supplements within 8 
weeks of being included in 
the trial 
- Laboratory values more than 
10% outside the normal 
range for transaminases, 
thyroid hormones, C-reactive 
protein, or bleeding 
parameters 
- Another severe intercurrent 
illness 
- Co-morbidities: not 
reported  
al and 
psychosocial 
intervention
s; 
  
psychosocia
l 
interventio
ns; 
 
 
 
Follow
 
Study
 
Addington
Addington
Amminger
Bechdolf
Hooker
Hooker
McGlashan
McGorry
McGorry
McGorry
Miklowitz
Morrison
O`Brien
Ruhrmann
Tsujino
Van der Gaag
Woods
Woods
 
Pooled 
(g
 
 
Heterogeneity
 
 
Between
Table 2 Within-group effect sizes at different follow-ups for improvements in functional outcome 
Note. * < 0.05, ** < 0.01, ***< 0.001; Effect sizes are presented in a way that positive values indicate an improvement in functional outcome. 
Abbreviations: CG, control group; EG, experimental group; gw: standardized mean difference for pre-post improvements in the respective group; 
 p=0.83 p=0.29 p=0.91 
  
Psychological interventions (PSY) 
Study Coun
-try 
De-
sign 
In- & exclusion 
criteria 
Sample 
size 
Sample 
characteristics 
Inter-
vention 
Control 
group 
Follow-up 
(months after 
baseline); 
Dropout-rate 
(Post-
therapy) 
Extracted 
outcome 
 
Morrison 
et al., 
2004 [x], 
2007 [x]; 
 
GE 1
- 
 
 
 
UK RCT Inclusion criteria: 
- Risk for psychosis (PANSS) 
Exclusion criteria: 
- < 16 years, > 36 years 
- Current or past receipt of 
antipsychotic medication 
60 
EG: 37 
CG: 23 
- Age (yrs.):  
EG: 20.6±4.9 / CG: 
21.5±5.2 (Age 
group: ADULT) 
- Gender: 
(male): EG: 60% / 
CG: 83% 
- Co-morbidities: not 
reported 
CBT + 
monitoring; 
26 sessions, 
6 months 
Monitoring; 
monthly  
6, 12, 36; 
EG / CG: 30% 
/ 30% 
TR (PANSS) 
Addington 
et al., 
2011 [x]; 
Marshall 
et al., 
2012 [x]; 
 
GE 1
- 
 
 
CAN RCT Inclusion criteria 
- 14 to 30 years 
- Risk for psychosis (SIPS) 
Exclusion criteria 
- Lifetime or  
current axis-I psychotic 
disorder 
- Prior treatment with an 
antipsychotic 
- IQ < 70 
- Past/current central nervous 
system disorder 
51  
EG: 27 
CG: 24  
- Age (yrs.): EG: 
20.8±4.5 / CG: 
21.1±3.7 (Age 
group: ADULT) 
- Gender (male): EG: 
67% / CG 75% 
- Co-morbidities (EG 
/ CG): mood 
disorders: 26% / 
26%, alcohol abuse: 
18% / 18%, 
cannabis abuse: 
10% / 10% 
CBT; 
max. 20 
sessions 
(mean=12±6
.2, range=1-
26),  
6 months 
Supportive 
Therapy: 
coping with 
current 
problems, 
psycho-
education; 
20 sessions, 
6 months 
6, 12, 18;  
EG / CG: 30% 
/ 33%,  
TR (SIPS), FO 
(GAF & SFS)  
Morrison 
et al., 
2012, 
UK RCT Inclusion criteria: 
- At-risk for psychosis 
(CAARMS) 
288 
EG: 144 
CG: 
- Age (yrs.): EG: 
20.7±4.2 / CG: 
20.8±4.5 (Age 
CBT + 
Monitoring; 
Max. 26 
Monitoring; 
monthly 
 
6, 12, 18, 24; 
EG / CG: 33% 
/ 31% 
TR (CAARMS 
or reports 
from family 
Tab. 1 Characteristics of studies included in the meta-analysis 
 [x]; 
Morrison 
et al., 
2011, 
2013 [x]; 
 
GE 1
+
 
- 14-35 years 
- Help-seeking 
Exclusion criteria: 
- Current or previous receipt of 
antipsychotic drugs 
- Moderate to severe learning 
disability 
- Organic impairments 
- Insufficient English 
144 group: ADULT) 
- Gender: (male): EG: 
62% / CG: 63% 
- Co-morbidities 
(total sample, >5%): 
Depressive 
disorder: 34%, 
dysthymic disorder: 
7%, panic disorder 
with agoraphobia: 
6%, panic disorder 
without 
agoraphobia: 11%, 
social phobia: 11%, 
specific phobia: 
11%, generalized 
anxiety disorder: 
9%, obsessive 
compulsive 
disorder: 8% 
sessions, 6 
months; 
plus up to 4 
booster-
sessions in 
the 
following 6 
months; 
 
 doctors), FO 
(GAF) 
Bechdolf 
et al.,  
2012 [x]; 
Bechdolf 
et al., 
2007 [x]; 
 
GE 1
-
 
GER RCT Inclusion criteria: 
- At least one of 10 thought or 
perceptional basic symptoms 
(ERIraos) and/or  
- Reduction in the GAF Score 
(DSM-IV) of at least 30 points 
within the past year and at 
least one of these risk factors: 
first-degree relative with 
schizophrenia  /schizophrenia 
spectrum disorder or pre-
/perinatal complications;  
Exclusion criteria: 
- APS or BLIPS 
- Present or past diagnosis of a 
psychotic disorder, bipolar 
disorder, organic brain 
128  
EG: 63 
CG: 65 
- Age (yrs.): EG: 
25.2±5.4 / CG: 
26.8±6.2 (Age 
group: ADULT) 
- Gender: (male): 
62% / 65%  
- Co-morbidities: not 
reported 
 
Integrated 
treatment: : 
Individual 
CBT, multi- 
family 
psycho-
education 
(group), 
social skills 
training 
(group), 
cognitive 
remediation 
25 sessions, 
12 months 
Supportive 
counselling: 
coping with 
current 
problems, 
basic 
psycho-
education; 
30 sessions, 
12 months 
 
6, 12, 18, 24; 
EG / CG: 19%, 
/ 
12%  
TR (DSM-IV), 
FO (SAS II) 
disorder, substance 
dependence 
- Mental retardation 
- Previous treatment with 
antipsychotics 
- Acute suicidality 
- < 17 years, > 35 years 
Van der 
Gaag et 
al., 2012 
[x]; 
Rietdijk et 
al., 2010 
[x]; 
 
GE 1
++
 
 
NL RCT Inclusion criteria 
- 14 to 35 years 
- At-risk for psychosis (CAARMS 
2006)  
- SOFAS score ≤ 50 and/or a 
reduction by 30% for at least 
1 month in the past year 
Exclusion criteria: 
- Current or previous use of 
antipsychotic medication with  
≥ 15 mg cumulative 
haloperidol equivalent 
- Severe learning impairment 
- Problems due to an organic 
condition 
- Insufficient competence in 
Dutch;  
- History of psychosis 
201  
EG: 98 
CG: 
103 
- Age (yrs.): EG: 
22.9±5.6 / CG: 
22.6±5.5 (Age 
group: ADULT) 
- Gender (male): EG: 
50% / CG:   
49% 
- Co-morbidities: 
(total sample, > 
5%): Anxiety 
disorders: 27%, 
depression: 26%, 
personality 
disorders: 8%, 
ADHD: 7%, 
addiction problems: 
6%;  
CBT + 
Treatment 
As Usual 
(TAU);  
max. 26 
sessions, 
weekly; 
6 months; 
additional 
evidence-
based 
treatment 
for axis-I 
and axis-II 
disorders; 
Treatment 
As Usual 
(TAU);  
additional 
evidence-
based 
treatment 
for axis-I 
and axis-II 
disorders; 
6, 12, 18; 
EG / CG: 15% 
/ 12% 
TR (CAARMS 
2006), FO 
(SOFAS) 
McGorry 
et al., 
2013 [x]; 
Yung et al. 
2011 [x]; 
 
GE 1
+ 
 
AUS RCT Inclusion criteria: 
- Age 14-30 years 
- Melbourne metropolitan area 
- Risk for psychosis (CAARMS 
2006) 
Exclusion criteria: 
- History of psychotic or manic 
episode 
- Medical condition that 
accounts for symptoms 
- Neurologic, biochemical or 
72 
EG: 44 
CG: 28 
- Age (yrs.): EG: 
18.0±2.7 / CG: 
18.8±3.7 (Age 
group: YOUTH) 
- Gender (male): EG: 
49% / CG: 47%  
- Co-morbidities: not 
reported 
EG : CBT + 
Placebo; 12 
months; 
CBT: Weekly 
to monthly 
basis; 50-60 
min./session
with the 
number of 
sessions not 
determined 
Supportive 
therapy + 
placebo; 12 
months; 
6, 12; 
EG: 34% / CG: 
32% 
TR (CAARMS 
2006), FO 
GAF) 
hematologic abnormalities 
- Serious co-existing illnesses 
- Lifetime antipsychotic dose of 
15mg or more of haloperidol  
- Any previous or current use 
of mood-stabilizing 
medication 
- History of severe drug allergy 
-  IQ<70 
- Pregnancy or lactation 
- Insufficient English  
in advance; 
Miklowitz 
et al., 
2014 [x]; 
O’Brien et 
al., 2014 
[x]; 
 
GE 1
+ 
USA RCT Inclusion criteria: 
- 12 and 25 years  
- Speaks and writes English 
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- Current schizophrenia or 
schizoaffective disorders 
- Developmental disorders 
- Substance use disorders 
- Neurological disorders 
129 
EG: 66 
CG: 63 
- Age (yrs.): EG: 
17.3±4.2 / CG: 
17.4±3.9 (Age 
group: YOUTH) 
- Gender (male): EG: 
59 % / CG: 56%  
- Co-morbidities (EG 
/ CG, >10%): 
depressive disorder 
(40% / 29%), 
anxiety disorders 
(42% / 50%), ADD 
(21% / 18%), 
learning disorders 
(11% / 7%) 
Family 
focused 
treatment; 
18 sessions 
à 60 
minutes, 6 
months 
 
Enhanced 
care; 
3 weekly 
psycho-
educational 
sessions, 
1 month 
6; 
EG: 17% / CG: 
25% 
 
TR (SIPS), FO 
(GAF) 
O’Brien et 
al., 2007 
[x]; 
 
GE 2
-
 
USA No 
CG 
Inclusion criteria: 
- 12-22 years  
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- DSM-IV diagnosis of a 
schizophrenia spectrum 
disorder 
- IQ<70 
- Current drug or alcohol 
dependence 
16   - Age (yrs.): 15.7 
(range: 12.5-18.5) 
(Age group: 
YOUTH) 
- Gender: (male): 
50%  
- Comorbidities  
(>10%): Mood 
disorders: 63%, 
depressive 
Psycho-
educational 
multi-family 
group; 
Weekly 
sessions à 
90 minutes, 
9 months 
- 9; 
45% declined 
or dropped 
out 
FO (GAF) 
- Current neurological disorder disorder: 31%, 
depressive disorder 
NOS: 19%, anxiety 
disorder NOS: 31%, 
generalized anxiety 
disorder: 19%, 
ADHD: 13%, eating 
disorder NOS: 19% 
/ 0% 
Hooker et 
al., 2014 
[x]; 
 
GE 2
-
 
USA  No 
CG 
Inclusion criteria: 
- 15-35 years 
- At-risk for psychosis (SIPS)  
Exclusion criteria: 
- Major medical / neurological 
illness 
- Non-fluent English 
- MR-contraindication 
- IQ<70 
28 
EG: 14 
CG: 14 
- Age (yrs.): 21.9±4.2 
(Age group: ADULT) 
- Gender (male): 50% 
CRT; neuro- 
and social-
cognitive 
computerize
d exercises; 
1h each day, 
5 
days/week, 
8 weeks; 
- 3; 
18%  
FO (Global 
Functioning 
Role and 
Social scales) 
Pharmacological studies - with antipsychotics – (MED)  
McGlasha
n et al., 
2006 [x]; 
McGlasha
n et al., 
2003 [x]; 
Woods et 
al., 2003 
[x]; 
 
GE 1
+
 
USA  RCT Inclusion criteria: 
- 12-45 years 
- Help-seeking 
- At-risk for psychosis (SIPS)¨ 
Exclusion criteria: 
- Past or current psychotic 
disorder 
- Treatable psychiatric disorder 
that could account for the 
prodromal symptoms 
- Suicidal or homicidal 
- Prodromal symptoms due to 
drug/alcohol use 
60 
EG:31 
CG: 29 
- Age (yrs.): EG: 
18.2±5.5 / CG: 
17.2±4.0 (Age 
group: YOUTH) 
- Gender (male): EG: 
68% / CG: 62% 
- Co-morbidities: 
Current substance 
abuse or 
dependence (EG: 
13% / CG: 4%)  
Olanzapine; 
5-15 mg/d, 
12 months; 
Additional 
individual  
and family 
psychosocial 
treatment, 
varied 
across sites; 
 
Placebo; 
12 months; 
Additional 
individual  
and family 
psychosocia
l treatment, 
varied 
across sites; 
 
2, 12, 24; 
EG: 55% / CG: 
35% 
 
TR (SIPS), FO 
(GAF) 
Woods et 
al., 2007 
[x]; 
 
USA No 
CG 
Inclusion criteria: 
- 13-40 years 
- Treatment seeking 
outpatients 
15 - Age (yrs.): 17.1±5.5 
(Age group: 
YOUTH) 
- Gender (male): 53% 
Aripiprazole
;  
Initial doses 
were 1st 
- 2; 
13% 
FO (GAF, SFS) 
GE 2
-
 - Met diagnostic criteria for a 
possible prodromal syndrome 
(SIPS) 
Exclusion criteria: 
- Past or current DSM-IV 
criteria for any lifetime 
psychotic disorder 
- Psychiatric disorder which 
could account for the 
symptoms 
- Symptoms primarily as 
sequelae to drug or alcohol 
use 
- Alcohol or drug misuse or 
dependence in the past 3 
months 
- Use of antipsychotic 
medication in the previous 3 
months 
- Change in dosage of any 
antidepressant within 6 
weeks, stimulant medication 
within 4 weeks or mood 
stabiliser within 4 weeks 
- Co-morbidities: not 
reported 
Week: 5 
mg/d, 2nd 
Week: 10 
mg/d 
3rd week: 
15 mg/d, 
4th Week: 
20mg/d and 
if needed to 
30mg/d; 
6 weeks  
Tsujino et 
al., 2013 
[x]; 
 
GE 2
-
 
JPN No 
CG 
Inclusion criteria: 
- 15-39 years 
- Help-seeking outpatients 
- At-risk for psychosis (SIPS) 
Exclusion criteria: 
- Previous diagnosis of any 
psychotic disorder (DSM-IV) 
- Symptoms fully accounted for 
by an Axis 1 disorder or 
sequelae of drug/alcohol use 
- Abuse of alcohol or drugs 
- Antipsychotic medication use 
11 - Age (yrs.): 26.7±6.5 
(Age group: ADULT)  
- Gender (male): 46% 
- Co-morbidities: not 
reported 
Perospirone
; dosing 
according to 
a flexible 
schedule; 
psychosocial 
therapy 
available;  
26 weeks 
- 6; 
25% 
 
FO (GAF) 
Pharmacological studies - combined with psychological interventions – (MED)  
McGorry 
et al. 2002 
[x]; Phillips 
et al., 
2007 [x]; 
 
GE 1
- 
 
AUS RCT Inclusion criteria: 
- 14-30 years 
- Live in the Melbourne 
metropolitan area 
- Risk for psychosis (CAARMS) 
Exclusion criteria: 
- Previous psychotic or manic 
episode 
- Previous treatment with an 
antipsychotic or mood 
stabilizing agent 
- Substance-induced psychotic 
disorder 
- IQ<70 
- Inadequate command of 
English 
59 
EG: 31 
CG: 28 
- Age (yrs.): EG: 
20±4/ CG: 20±3 
(Age group: ADULT) 
- Gender (male): EG: 
65% / CG: 50% 
Risperidone 
(1-2 mg/d) +  
CBT + 
Needs-
based 
intervention
(NBI); 
6 months; 
NBI on-
going;  
Needs-
based 
interventio
n (NBI);  
6 months; 
NBI on-
going; 
 
6, 12, 36-48; 
months; 
Drop-out 
rate: not 
reported, 
41% non-
adherent to 
Risperidone;  
 
FO (GAF) 
Ruhrmann 
et al., 
2007 [x]; 
 
GE 1
-
 
GER RCT Inclusion criteria: 
- Older than 18 years  
- Risk for psychosis (ERIraos) 
Exclusion criteria: 
- Lifetime DSM–IV diagnosis of 
schizophrenia spectrum 
disorder, brief psychotic 
episode (>1 week), delirium, 
dementia, amnestic and 
other cognitive disorders 
- Mental retardation 
- Mental disorders due to a 
general medical condition or 
psychotropic substances 
- Abuse of alcohol or drugs 
within the past 3 months or 
the past 4 weeks for cannabis 
- Any lifetime continuous 
treatment with high-potency 
124 
EG: 65 
CG: 59 
- Age (yrs.): EG: 
25.1±6.6 / CG: 
26.1±6.1 (Age 
group: ADULT) 
- Gender: (male): 
48% / 60% 
- Co-morbidities: not 
reported 
Needs-
focused 
intervention 
+ 
Amisulpride; 
12 weeks; 
50-800 
mg/d, with 
increments 
of 50 mg at 
first step 
and 100 mg 
at further 
steps; 
dosage was 
increased as 
long as APS 
and BLIPS 
were 
Needs-
focused 
interventio
n; 
12 weeks 
3; 
EG: 29% / CG: 
49%  
FO (GAF) 
antipsychotics (> 1 week) or 
antipsychotics during 6 
months prior to the study 
- Any contraindication for 
amisulpride  
- Women of childbearing risk 
not using contraception 
present;  
McGorry 
et al., 
2013 [x]; 
Yung et al. 
2011 [x]; 
 
GE 1
+ 
 
AUS RCT Inclusion criteria: 
- Age 14-30 years 
- Melbourne metropolitan area 
- Risk for psychosis (CAARMS, 
2005) 
Exclusion criteria: 
- History of psychotic or manic 
episode 
- Medical condition that 
accounts for symptoms 
- Neurologic, biochemical or 
hematologic abnormalities 
- Serious co-existing illnesses 
- Lifetime antipsychotic dose of 
15mg or more of haloperidol  
- Any previous or current use 
of mood-stabilizing 
medication 
- History of severe drug allergy 
- IQ<70 
- Pregnancy or lactation 
- Insufficient English  
71 
EG: 43
 
CG: 28 
- Age (yrs.): EG: 17.6 
±3.0) / CG: 18.8±3.7 
Age group: YOUTH) 
- Gender (male): EG: 
45% / CG: 47%  
- Co-morbidities: not 
reported 
EG: CBT + 
Risperidone 
(0.5-2 
mg/d);  
12 months; 
CBT: Weekly 
to monthly 
basis; 50-60 
min./session
; number of 
sessions not 
predetermin
ed; 
 
Supportive 
therapy + 
placebo;  
12 months; 
6, 12; 
EG 37% / CG: 
32% 
TR (CAARMS 
2006), FO 
GAF) 
Pharmacological studies - with nutritional supplements – (MED)  
Amminger 
et al., 
2010 [x]; 
Mossaheb 
et al., 
2013 [x]; 
AUT RCT Inclusion criteria: 
- At-risk for psychosis (PANSS) 
Exclusion Criteria: 
- History of previous psychotic 
disorder or manic episode  
- Substance-induced psychotic 
81 
EG: 41 
CG:40  
- Age (yrs.): EG: 
16.8±2.4 / CG: 
16.0±1.7 (Age 
group: YOUTH) 
- Gender (male): EG: 
34% / CG: 33% 
1.2 g/d ω-3 
PUFAS; 
12 weeks;  
9 additional 
sessions of 
psychologic
Placebo 
(coconut 
oil); 
12 weeks; 
psychologic
al and 
12;  
EG: 7% / 5%;  
TR (PANSS), 
FO (GAF) 
 GE 1
+
 
 
 
disorder 
- Acute suicidal or aggressive 
behavior 
- Current DSM-IV diagnosis of 
substance dependence 
(except cannabis 
dependence) 
- Neurological disorders  
- IQ<70 
- Structural brain changes 
apparent on magnetic 
resonance imaging 
- Previous treatment with an 
antipsychotic or mood-
stabilizing agent (>1 week) 
- ω-3 supplements within 8 
weeks of being included in 
the trial 
- Laboratory values more than 
10% outside the normal 
range for transaminases, 
thyroid hormones, C-reactive 
protein, or bleeding 
parameters 
- Another severe intercurrent 
illness 
- Co-morbidities: not 
reported  
al and 
psychosocial 
intervention
s; 
  
psychosocia
l 
interventio
ns; 
 
 
 
Note. * < 0.05, ** < 0.01, ***< 0.001; Effect sizes are presented in a way that positive values indicate an improvement in functional outcome. 
Abbreviations: CG, control group; EG, experimental group; gw: standardized mean difference for pre-post improvements in the respective group; 
 
Table 2 Within-group effect sizes at different follow-ups for improvements in functional outcome 
Follow-up 2 to 6 months 9 to 12 months 18 months 
 
Study 
 
 
EG gw 
 
CG gw 
 
EG gw 
 
CG gw 
 
EG gw 
 
CG gw 
Addington
x
a 0.18 -0.03 0.45 0.53 0.07 0.29 
Addington
x
b 0.36 0.25 0.28 0.37 0.92 0.43 
Amminger
x 
  7.62 2.97   
Bechdolf
x 
  0.44 0.60   
Hooker
x
a -0.25      
Hooker
x
b -0.06      
McGlashan
x
 0.54 0.27 0.87 0.52   
McGorry
x 
  0.01 0.35 0.34 0.03 
McGorry
x
Risperidone 0.29 0.90 1.26 0.57   
McGorry
x
CBT 0.09 1.52     
Miklowitz
x
 2.79 2.24     
Morrison
x
 0.62 0.84 0.72 0.57 1.04 0.77 
O`Brien
x 
  0.87    
Ruhrmann
x
 0.72 0.19     
Tsujino
x
 0.97      
Van der Gaag
x
 0.99 0.72 1.20 1.19 1.66 1.46 
Woods
x
a -0.06      
Woods
x
b 1.40      
 
Pooled gw 
(gw , 95% CIs) 
 
 
0.62***  
(0.26,0.98) 
 
0.68** 
(0.26,1.10) 
 
0.84*** 
(0.41,1.26) 
 
1.22*** 
(0.66,1.78) 
 
0.69  
(-0.01,1.39) 
 
0.64*  
(0.12,1.17) 
 
Heterogeneity 
 
 
Qw(13)=101.65*** 
I
2
=87% 
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Figure 1. Flow chart of the study selection process
10206 records identified through
database searching
3 records identified through other
sources
Records after duplicates removed (n=8452)
77 records screened 16 records excluded
61 full-text articles assessed
for eligibility
36 articles excluded
due to these reasons:
• Case-studies
(n=4)
• Naturalistic design 
(n=4)
• Study protocol
(n=10)
• Other outcome(s) 
(n=12)
• Mixed samples
(n=3)
• Overlapping sample 
(n=3)
25 articles included in the
review
Studies included in the
meta-analysis: 15 
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